Abstract 8-Cl-cAMP, a site-selective analogue of cAMP, decreased mdr-1 expression in multidrug-resistant human breast cancer cells. A sixfold reduction of mdr-1 mRNA expression by 8-Cl-cAMP began within 8 h of treatment and was associated with a decrease in the synthesis of P-glycoprotein and with an increase in vinblastine accumulation. A reduction in mdr-1 expression after 8-Cl-cAMP treatment was also observed in multidrug-resistant human ovarian cancer cell lines. 8-Cl-cAMP is known to change the ratio between the two regulatory subunits, RI and RH, of protein kinase A (PKA). We observed that RIa decreased within 24 h of 8-Cl-cAMP treatment, that RIIP increased after as few as 3 h of treatment, and that PKA catalytic activity remained unchanged during 48 h of 8-Cl-cAMP treatment. The results are consistent with the hypothesis that mdr-1 expression is regulated in part by changes in PKA isoenzyme levels. Although 8-Cl-cAMP has been used to differentiate cells in other model systems, the only differentiating effect that could be detected after 8-Cl-cAMP treatment in the MCF-7TH cells was an increase in cytokeratin expression. Evidence that the reduction of mdr-1 mRNA occurred at the level of gene transcription was obtained by measuring chloramphenicol acetyltransferase (CAT) mRNA in MCF-7TH cells transfected with an mdr-1 promoter-CAT construct prior to 8-Cl-cAMP treatment. Thus, 8-Cl-cAMP is able to downregulate mdr-1 expression and suggests a new approach to reversal of drug resistance in human breast cancer. (J. Clin.
Introduction
Advances in the treatment of metastatic breast cancer with standard dose cytotoxic therapy have been limited during the last 15 yr. Breast cancer is not inherently refractory to chemotherapy, since most women respond initially but later relapse and treatment failure occurs. Although multiple drug resistance mechanisms probably account for this, P-glycoprotein has been cited as playing a role in resistance in breast cancer ( [1] [2] [3] ). The product of the mdr-1 gene, P-glycoprotein, mediates multidrug resistance by enhanced outward transport of drugs of natural product origin (4) . P-glycoprotein has been demonstrated in human breast cancer cells selected in vitro for drug resistance (5) , and the protein has been observed in breast cancer samples (1, 2, 6) . Expression is typically found in previously treated breast cancers and less often in untreated breast cancer (2, 3, 7) . The present studies were undertaken to determine whether P-glycoprotein expression could be modulated in multidrugresistant human breast cancer cells.
Studies of the regulation and function of P-glycoprotein have demonstrated that the mdr-1 gene can be induced in various model systems. Beginning with the observation of increased mdr-l in regenerating rat liver (8) , multiple studies have demonstrated increased expression in response to various agents or environmental stimuli (9) (10) (11) (12) (13) . In contrast, decreased mdr-1 expression is seldom reported. Abraham et al. demonstrated a decreased mdr-1 level in a cell line transfected with a mutant regulatory subunit of protein kinase A (PKA)' ( 14) . Likewise, Kim reported a decrease in mdr-1 levels after treatment of P388 resistant cells with the PKA inhibitor H-87 (15) . Okabe-Kado et al. reported a 50% decrease in MRK-16 binding and an enhancement of drug sensitivity after treatment of multidrugresistant K562/VCR leukemic cells with erythroid differentiation factor, one of four agents which induced erythroid differentiation in the cells ( 16) . Schecter et al. reported that xenografts of a mammary adenocarcinoma cell line had a lower level of mdr-1 expression than was observed in the cells cultured in vitro (17) . Taken together, these experiments demonstrate that the mdr-1 gene can be regulated by diverse agents but give little clue to the mechanism whereby this regulation occurs. The finding that the differentiating agents sodium butyrate and retinoic acid increased levels of mdr-1 in cell lines derived from colon cancer, kidney cancer, and neuroblastoma (9, 10) (unpublished results) gave rise to the hypothesis that differentiating agents could alter mdr-1 expression in a cancer cell toward the level found in the tissue of origin. Thus, in neuroblastoma and in colon and kidney cancer cell lines, the addition of differentiating agents could increase mdr-1 because the normal adrenal, colon, and kidney express mdr-l/P-glycoprotein. We proposed that where normal tissue expression is low, as in the normal ovary or breast (6, (18) (19) (20) , the effect of some differentiating agents on malignant cells could be to decrease levels of mdr-1. We found that 8-Cl-cAMP, a differentiating agent in human leukemic cells (21) systems (21) (22) (23) . The differentiating effect of 8-Cl-cAMP is thought to be mediated by changes in the levels of the regulatory subunits of cAMP-dependent PKA. PKA exists in the holoenzyme state as four subunits, two catalytic and two regulatory (24) . Two classes of PKA (type I and type U) are composed of distinct regulatory subunits, I and II, and a common catalytic subunit. In the normal setting, cAMP binds to two sites on the regulatory subunits and results in dissociation of mainly type I PKA, releasing the catalytic subunit from the regulatory subunit (RI), thereby activating the enzyme for phosphorylation of various proteins. 8-Cl-cAMP binds to the two sites on RI with a higher affinity than cAMP and results in activation of the type I PKA, with subsequent downregulation of both the protein and mRNA for RI (22, (25) (26) (27) (28) . 8-Cl-cAMP also binds, with a high affinity, one of the two sites of RII, but binds the other poorly. This results in an increase of type II PKA holoenzyme. Moreover, RU (or PKA type U) is translocated into the nucleus within 10 min of addition of 8-Cl-cAMP, where transcription of different genes may be affected (25) .
We examined the effect of 8-Cl-cAMP on PKA activity, mdr-l expression, P-glycoprotein synthesis, and vinblastine accumulation in MCF-7TH cells.
Methods
Cell lines and cell culture conditions. The MCF-7 human breast cancer cell line was obtained from Marc Lippman (Georgetown University, Washington, D.C.), having been frozen in its 66th passage (29 T., the optical density of cells harvested at the time treatment was started (T.); and T, the optical density of the control cells.
RNA extraction, electrophoresis, and blotting. Total cellular RNA was extracted from cells by homogenizing in guanidine isothiocyanate followed by centrifugation over a cesium chloride cushion. Total RNA was electrophoresed in 1% agarose, 6% formaldehyde gels, which were subsequently stained with 2 .g/ml ethidium bromide to allow inspection of the quantity and quality of RNA (32) .
Northern blot and RNase protection analysis. For Northern blot analysis, a 1.4-kb cDNA containing sequences from the middle third of mdr-1 /Pgp subcloned in a pGEM vector was used for riboprobe synthesis. Hybridization was performed as previously described (9) . For RNase protection, we utilized a 1-kb genomic sequence from the 5' end of the gene subcloned into pGEM-3 and linearized with PvuU (33). The 1-kb PstI fragment contains a promoter region of the human mdr-1 /Pgp gene. As a control for RNA loading, an antisense molecule (cRNA) was synthesized from p36B4 using T7 polymerase (34) . Because it is not affected by estrogen, 36B4 has been utilized as a control by investigators in studies of mRNA regulation in MCF-7 cells (35) . Hybridization and RNase digestion were performed as previously described (9) . Quantitation was performed using a densitometer (Fotodyne, New Berlin, WI).
Quantitative polymerase chain reaction. A quantitative PCR assay was utilized as previously described (36, 37) . Briefly, reverse transcription of l-,ug total RNA was initiated with random primers using M-MTLV reverse transcriptase. The resulting cDNA was diluted 2,000-fold and amplified 30 cycles using fi-tubulin-specific 5 ' primer (nucleotides 342-360, TTCTGTCCTGGATGTGGTA) and 3' primer (nucleotides 521-539, AAGTGTCTGACACCGTGGT) (38) . The PCR products were electrophoresed in agarose-NuSieve (FMC Bioproducts, Rockland, ME) gels and then stained with ethidium bromide for densitometric analysis.
Immunoprecipitation and metabolic labeling. Untreated cells or cells treated with 8-Cl-cAMP were labeled as previously described (39) MA) in 4 ml of methionine-free DME without serum for 16 h. 8-ClcAMP was added 72 h before harvesting the cells and continued during cell labeling. After harvesting cells in RIPA buffer (1% Triton X-100, 0.1% NaDodSO4, 1% sodium deoxycholate, 0.15 M NaCl, 20 mM TrisHCl, pH 7.2), immunoprecipitation was carried out with a polyclonal antibody raised against recombinant protein fragments (40); the product was analyzed on a 7% polyacrylamide gel.
Immunoblotting. Cells were homogenized in 250 mM sucrose, 10 mM Tris pH 7.5, 1% aprotinin, and membrane protein obtained for immunoblotting as previously described (41) . Samples (20 ug) were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose. The blots were blocked for 2 h with 3% BSA in TTBS (0.1% Tween 20, mM Tris-HCI, pH 7.5, 150 mM NaCl) prior to incubating for 1 h in a 1:2,000 dilution of the primary polyclonal anti-Pgp antibody, 4007 (40) . After washing with TTBS, the blots were incubated for 1 h in a 1:4,000 dilution of donkey anti-rabbit horseradish peroxidaseconjugated secondary antibody. Immunoreactive protein was detected using an enhanced chemiluminescence method (ECL; Amersham Corp., Arlington Heights, IL).
Immunohistochemical staining. For determination of keratin, cells were plated on poly-L-lysine-coated slides in quadriperm plates, treated with 8-Cl-cAMP for 72 h, and fixed according to the antibody manufacturer's directions. Keratin was stained using monoclonal anti-cytokeratin peptide 18 antibody (Sigma Chemical Co.). Bound antibody was detected using the ABC immunoperoxidase technique (42) .
Drug accumulation assay. Drug accumulation and efflux studies were performed in six-well dishes as previously described by Fojo et al. (43) .
Immunoprecipitation. Immunoprecipitation of RIIHB was performed by the method previously described (21 (Fig. 1 A) . The decrease in mdr-l can be compared to that of the control gene 36B4 (Fig. 1 B) (35) .
The decrease in mdr-1 expression was accompanied by a decrease in P-glycoprotein synthesis that was dose dependent, as shown in Fig. 2. [35S ] methionine labeling of cells was examined after 72 h treatment with 8-Cl-cAMP, in doses ranging from 0.5 to 25 ,uM. Decreased synthesis was seen at all doses, with greater inhibition observed at higher doses of 8-Cl-cAMP.
The dose-dependent decrease in Pgp synthesis was accompanied by a decrease in cell growth. Although this observation has been reported associated with the differentiating effect of 8-Cl-cAMP, some have ascribed the growth inhibition seen with 8-Cl-cAMP to toxic effects of its adenosine metabolite (45, 46) . Thus, to evaluate whether 8-Cl-adenosine could be mediating the reduction in mdr-1 expression, cell growth assays and Northern analysis were performed. Cell growth assays in parental MCF-7 and MCF-7TH cells showed significant growth inhibition with both 8-Cl-cAMP and 8-Cl-adenosine. (Fig. 4 A) . Thus, the metabolite 8-Cl-adenosine may account for some of the growth inhibition observed in MCF-7TH cells but cannot account for the regulation of mdr-1 expression. Although a modest reduction in expression of the control gene, 36B4, was also observed after 8-Cl-cAMP treatment, no modulation was seen in the expression of a second control gene, 6-tubulin. Fig. 4 B shows the results of a separate experiment in which mdr-1 was reduced fivefold by 25 MM 8-Cl-cAMP, while ,f-tubulin levels were unchanged. In addition, the effects of the P-glycoprotein antagonist, verapamil (Knoll Pharmaceuticals, Whippany, NJ), and of the nonspecific protein kinase inhibitor, H-7 (Seikagaku America, Inc., Rockville, MD), were examined (47). Neither agent downregulated mdr-l expression.
After demonstrating downregulation of mdr-I mRNA levels by 8-Cl-cAMP, we evaluated drug transport by vinblastine accumulation and efflux studies. Because of the long half-life of Pgp (72 h) (39) , functional studies were performed after 5 and than the sixfold increase observed after incubation in verapamil (Fig. 5 A) . Fig. 5 B demonstrates that mdr-1 mRNA continues to be downregulated after 10 d of 8-Cl-cAMP treatment. However, the incomplete reversal of accumulation in A suggests that Pgp persists despite the downregulation of mdr-1. This suggestion was confirmed by immunoblotting, which demonstrated reduction to only 25% of control levels of Pgp after 10 d of treatment with 8-Cl-cAMP (Fig. 5 B) . To (Fig. 6 ). An electron microscope (Phillips 201; Phillips Technologies, Cheshire, CT) was used to examine parental MCF-7 cells and treated and untreated MCF-7TH cells. In both the parental MCF-7 cells and the untreated drug-resistant subline, features of differentiation such as attachments, microvilli, and organelles were observed. However, parental MCF-7 cells (Fig. 6 A) appeared somewhat more differentiated than the drug-resistant subline (Fig. 6 B) , as evidenced by better orientation and more well-developed attachments in the MCF-7 cells. By light microscopy, MCF-7 parental cells also appeared more differentiated than the MCF-7TH cells, with circular structures suggestive of gland formation present in the parental (Fig. 6 C) but not in the resistant subline (Fig.  6 D) . Immunohistochemical analysis of cytokeratin 18 showed higher levels in the parental (Fig. 6 E) subline (Fig. 6 F) . After treatment of MCF-7TH Cl-cAMP, electron microscopy studies showed cytoplasmic filaments (not shown). Expression 18 increased after treatment of the MCF-7TH ce cAMP (Fig. 6 G) (51) . These studies have demonstrated an immediate translocation of RII13 to the nucleus, followed by a decrease in RIa protein and mRNA (22, 25, 26, 51) . Thus, we evaluated the levels of the RIa and RIIP subunits by photoaffinity labeling followed by immunoprecipitation. As shown in Fig.  7 , the RIa levels were markedly reduced after 24 h of 8-ClcAMP treatment, while the RII3, levels increased within 3 h of treatment. Densitometric analysis showed that RIa decreased to 50% of the control level after 24 h treatment and RIIP increased twofold compared with the control level after 6 h of 8-Cl-cAMP -treatment.
-PIP To determine whether changes in the catalytic activity of PKA are involved in the effect of 8-Cl-cAMP, we examined phosphotransferase activity in cells during 8-Cl-cAMP treatment, using kemptide as a substrate in the presence and absence of a saturating concentration of cAMP and in the presence and absence of heat-stable protein kinase inhibitor (21) . This method of assay gives accurate determination of the relative levels of dissociated catalytic subunit activity and total catalytic activity. The PKA activity ratio, the ratio of activity in the absence of added cAMP to that in the presence of cAMP, measures the degree of free catalytic subunit release. As shown in Fig. 8 , no appreciable change in the PKA ratio during 48 h of 8-Cl-cAMP treatment was observed, while at 5 d of treatment, 9 10 the ratio showed a 50% increase, consistent with an increase in free catalytic subunit. These results show that during the initial 8-Cl-cAMP time of 8-Cl-cAMP treatment (up to 48 h) there was no increase ites the accumuin free catalytic subunit release. .e control cells
To evaluate the generality of the effect of 8-Cl-cAMP in )f 100%. The reducing mdr-1 expression, we studied multidrug-resistant ovare noted on each ,es to 250% and ian cancer cells. We chose ovarian cells because studies in [P, but does not normal and malignant ovarian tissues have found low levels of orbars present mdr-1/Pgp, similar to the levels in the breast (19, 20) . As Cl-cAMP treatshown in Fig. 9 , decreased expression of mdr-1 was observed lysis following In this work, we have described the effect of 8-Cl-cAMP on expression of the mdr-1 gene. We have demonstrated that mRNA expression is decreased in MCF-7TH cells within hours of treatment with 5 pLM 8-Cl-cAMP, that the effect is dose dependent, and that synthesis of P-glycoprotein decreases in concert with the decrease in mdr-1 mRNA. These effects are manifested by an increase in drug accumulation and a decrease in drug efflux. We have not defined the mechanism by which 8-Cl-cAMP modulates mdr-l expression, but it appears to be transcriptionally mediated. Several possibilities can be proposed for the effect of 8-Cl-cAMP on MCF-7TH cells: (1) of a toxic metabolite, (2) differentiation in parallel with a decrease in RI levels, (3) up-or downregulation of PKA activity, and/or (4) transcriptional regulation through the RII/PKA type H holoenzyme.
Two previous reports suggested that the activity of 8-ClcAMP is mediated by a toxic metabolite, 8-Cl-adenosine (45, 46) . However, several lines of experimental evidence argue against a role for this metabolite in regulating mdr-I expression. MDR promoter activity, assayed in MCF-7 cells, was decreased by 8-Cl-cAMP but not by 8-Cl-adenosine (54) . In MCF-7TH cells, 8-Cl-adenosine is a growth inhibitor but has no effect on mdr-1 expression or promoter activity. These studies oppose the hypothesis that 8-Cl-adenosine is the mediator of the reduction in mdr-l observed in MCF-7TH cells.
The second possibility, differentiation, has been proposed as a mechanism of 8-Cl-cAMP action in several model systems. Elevated levels of type I PKA have been linked with the malignant phenotype, whereas elevated levels of type II PKA have been linked with differentiation (5 1). It has been proposed that the phenotypical alterations resulting from regulation of these two subtypes occur through changes in gene expression rather than through changes in phosphorylation (25, 51) . In MCF-7TH cells, the only evidence that could be obtained for differentiation was an increase in keratin expression. The higher level of keratin expression, which approximates that of parental MCF-7 cells, is consistent with differentiation of a ductal epithelial cell (55). The decreased expression of the RI subunit of PKA that results from 8-Cl-cAMP treatment in multiple model systems has been characterized as a differentiation marker (51) . Thus, the reduced RI observed in MCF-7TH cells could be consistent with differentiation. Despite the less differentiated appearance of MCF-7TH cells relative to parental MCF-7 cells, no other differentiation markers were altered by 8-Cl-cAMP treatment.
A third possible mechanism for 8-Cl-cAMP action occurs through regulation of the catalytic activity of PKA. Our results showed that the amount of free C subunit remained unchanged during 48 h of 8-Cl-cAMP treatment. However, the suppression of mdr-l expression was observed as early as 8 h post-8-ClcAMP treatment. Thus, it appears that the triggering mechanism of 8-Cl-cAMP leading to the suppression of mdr-l expression does not involve up-or downregulation of the catalytic activity of PKA.
A fourth mechanism whereby 8-Cl-cAMP might alter mdr-1 expression occurs through the RIIP subunit/PKA type H holoenzyme. Our data support this possibility: an increase in RIIH subunit occurred as early as 3 h after 8-Cl-cAMP treatment; this increase preceded the suppression of mdr-1 expression that was detected at 8 h after 8-Cl-cAMP treatment. 8-ClcAMP renders the C subunit available for the RII subunit to form a PKA type II holoenzyme by downregulation of the RI subunit (27, 28) . It (51) . Thus, the action of 8-Cl-cAMP in the mndr-l suppression may involve a transcriptional mechanism mediated through PKA type H. The results demonstrating modulation of the mdr-1 promoter are consistent with such a mechanism. CRE consensus sequences have not been described in the mdr-l promoter (44, (56) (57) (58) . As suggested earlier, 8-Cl-cAMP may regulate a nuclear-binding protein that in turn downregulates mdr-1 expression. However, emerging data suggest that gene rearrangements have occurred proximal to the mdr-1 promoter in some mdr-1 overexpressing cell lines (T. Fojo, personal communication). If such a rearrangement occurred in the MCF-7TH cells, the effect may have been to bring mdr-I under control of a cAMP response element. Sequencing of the region 5' to mdr-1 is currently under way in these cells.
In conclusion, the data implicate the role of RII/3 subunit/ PKA type II in regulating mdr-l expression. The mechanism and sites of its action remain to be elucidated. These data are significant in that a new approach to reversing multidrug resistance is described in the use of 8-Cl-cAMP to inhibit expression of mdr-l/P-glycoprotein. A mechanism for decreasing mdr-l expression would be a welcome addition to the therapeutic options for refractory breast cancer.
